The role of antioxidant, coenzyme Q10, in suppressing invasion of temozolomide resistant rat glioma
2019
Аутори:
Stojković Burić, SonjaPodolski-Renić, Ana
Dinić, Jelena
Stanković, Tijana
Jovanović, Mirna
Hadžić, Stefan
Ayuso, Jose
Virumbrales-Muñoz, María
Fernández, Luis
Ochoa, Ignacio
Pérez-García, Victor
Pešić, Milica
Тип документа:
Конференцијски прилог (Објављена верзија)
,
© 2019 by the COST Action CA17104
Метаподаци
Приказ свих података о документуАпстракт:
Development of chemoresistance and the invasion of cancer cells into surrounding brain tissue are major obstacles to successful glioma treatment. New therapeutic approaches are warranted to improve the survival of glioma patients. The purpose of this study was to assess the potential of lipophilic antioxidant coenzyme Q10 (CoQ10) to increase sensitivity to temozolomide (TMZ) and suppress glioma cells invasion. Therefore, we have developed TMZ resistant RC6 rat glioma cell line with altered antioxidant capacity and high invasion potential. CoQ10 in combination with TMZ exerted a synergistic effect additionally confirmed in a 3D model of microfluidic devices. Co-treatment with TMZ increased
expression of mitochondrial antioxidant enzymes in RC6 cells. The anti-invasive potential was studied by gelatin degradation and 3D spheroid invasion assays. Inhibition of MMP9 gene expression as well as decreased N-cadherin and vimentin protein expression implied that CoQ10 can suppress invasiveness and the epithelial to mesenchymal transition in RC6 cells. Therefore, CoQ10 supplementation could be used with standard glioma treatment due to its potential to inhibit cancer cells invasion through modulation of the antioxidant capacity.
Финансирање / пројекти:
- Идентификација молекуларних маркера за предикцију прогресије тумора, одговора на терапију и исхода болести (RS-MESTD-Integrated and Interdisciplinary Research (IIR or III)-41031)
У:
- Abstract book: STRATAGEM CA17104: New diagnostic and therapeutic tools against multidrug-resistant tumours: First Working-Group Meeting WG1 - WG4; 2019 Jan 30-31; Turin, Italy. COST Action CA17104; 2019. p. 32.